ACHV NASDAQ
Achieve Life Sciences, Inc.
1W: -4.9%
1M: +2.7%
3M: +56.1%
YTD: +24.4%
1Y: +130.6%
3Y: +13.6%
5Y: -20.7%
$6.18
+0.00 (+0.00%)
Weekly Expected Move ±7.7%
$5
$6
$6
$7
$7
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$634.4M
52W Range2.37-7.11
Volume1,220,010
Avg Volume1,807,766
Beta2.22
Dividend—
Analyst Ratings
Company Info
CEOAndrew D. Goldberg
Employees28
SectorHealthcare
IndustryBiotechnology
IPO Date1995-10-12
Websiteachievelifesciences.com
22722 29th Dr. SE
Bothell, WA 98021
US
Bothell, WA 98021
US
14256861500
About Achieve Life Sciences, Inc.
Achieve Life Sciences, Inc. operates as a clinical-stage pharmaceutical firm, concentrating on the development and market introduction of cytisinicline. This compound is aimed at assisting with smoking cessation and nicotine dependence, with commercial activities spanning Canada, the United States, and the United Kingdom. Cytisinicline is a naturally occurring alkaloid, which functions by engaging with nicotine receptors in the brain to lessen the intensity of nicotine withdrawal symptoms. The company holds licensing agreements with Sopharma AD and the University of Bristol. Its corporate headquarters are located in Vancouver, Canada.
Latest News
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Waldman Reid Alexand | 0 | — | 2026-05-29 | |
| Farrow Jeffrey S | 0 | — | 2026-05-29 | |
| Waldman Reid Alexand | A-Award | 47,250 | $5.24 | 2026-05-29 |
| Farrow Jeffrey S | A-Award | 47,250 | $5.24 | 2026-05-29 |
| Martin Christopher N | A-Award | 47,250 | $5.59 | 2026-05-11 |